The controversy and business opportunity in polygenic embryo selection lie in interpreting genetic data, not in the physical sequencing. Companies are competing on the quality and scope of their predictive models for health and traits, which they apply to data from established lab processes.
Related Insights
The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.
The introduction of genomics, which uses DNA analysis to predict a calf's future traits, has revolutionized dairy breeding. The rate of genetic improvement jumped from approximately $13 per cow per year to $100. This leap in efficiency allows for rapid selection for traits like higher yields and disease resistance.
The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.
A significant portion of biotech's high costs stems from its "artisanal" nature, where each company develops bespoke digital workflows and data structures. This inefficiency arises because startups are often structured for acquisition after a single clinical success, not for long-term, scalable operations.
The winning strategy in the AI data market has evolved beyond simply finding smart people. Leading companies differentiate with research teams that anticipate the future data requirements of models, innovating on data types for reasoning and STEM before being asked.
The future of valuable AI lies not in models trained on the abundant public internet, but in those built on scarce, proprietary data. For fields like robotics and biology, this data doesn't exist to be scraped; it must be actively created, making the data generation process itself the key competitive moat.
Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in
The ability to select embryos fundamentally changes parenthood from an act of acceptance to one of curation. It introduces the risk of "buyer's remorse," where a parent might resent a child for not living up to their pre-selected potential. This undermines the unconditional love that stems from accepting the child you're given by fate.
As algorithms become more widespread, the key differentiator for leading AI labs is their exclusive access to vast, private data sets. XAI has Twitter, Google has YouTube, and OpenAI has user conversations, creating unique training advantages that are nearly impossible for others to replicate.
A major frustration in genetics is finding 'variants of unknown significance' (VUS)—genetic anomalies with no known effect. AI models promise to simulate the impact of these unique variants on cellular function, moving medicine from reactive diagnostics to truly personalized, predictive health.